Get the Stockscreener App
7.895
1.44%
-0.115
Adaptive Biotechnologies Corp stock is traded at $7.895, with a volume of 649.71K.
It is down -1.44% in the last 24 hours and up +11.20% over the past month.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
See More
Previous Close:
$8.01
Open:
$8.03
24h Volume:
649.71K
Relative Volume:
0.49
Market Cap:
$1.18B
Revenue:
$177.28M
Net Income/Loss:
$-195.24M
P/E Ratio:
-5.8918
EPS:
-1.34
Net Cash Flow:
$-114.54M
1W Performance:
+1.87%
1M Performance:
+11.20%
6M Performance:
+88.42%
1Y Performance:
+121.15%
1-Day Range:
$7.66
$8.19
1-Week Range:
$7.27
$8.31
52-Week Range:
$2.28
$8.33
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Name
Adaptive Biotechnologies Corp
Sector
Industry
Phone
206-659-0067
Address
1165 EASTLAKE AVE E, SEATTLE, WA
Compare ADPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
7.895 | 1.18B | 177.28M | -195.24M | -114.54M | -1.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.86 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.63 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
651.92 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.00 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.86 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Dec-21-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Underperform |
| Jun-03-22 | Initiated | Piper Sandler | Neutral |
| Feb-16-22 | Reiterated | BTIG Research | Buy |
| Feb-16-22 | Reiterated | BofA Securities | Buy |
| Feb-16-22 | Reiterated | Goldman | Neutral |
| Feb-16-22 | Reiterated | JP Morgan | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Mar-03-21 | Downgrade | Goldman | Buy → Neutral |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-03-20 | Initiated | Goldman | Buy |
| Jul-23-19 | Initiated | BTIG Research | Buy |
| Jul-22-19 | Initiated | BofA/Merrill | Buy |
| Jul-22-19 | Initiated | Cowen | Outperform |
| Jul-22-19 | Initiated | Goldman | Neutral |
| Jul-22-19 | Initiated | Guggenheim | Buy |
| Jul-22-19 | Initiated | William Blair | Outperform |
View All
Adaptive Biotechnologies Corp Stock (ADPT) Latest News
It makes sense and dollars to buy Adaptive Biotechnologies Corp (ADPT) stock - SETE News
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences - Yahoo Finance
Analysts review Adaptive Biotechnologies Corp’s rating - Knox Daily
Adaptive Biotechnologies Corp (ADPT) Stock: Navigating a Year of Stock Volatility - The InvestChronicle
Sumitomo Mitsui Trust Group, Inc. Reduces Stake in Adaptive Biot - GuruFocus.com
Stock Performance Spotlight: Adaptive Biotechnologies Corp (ADPT) Ends the Day at 7.70, Down by -0.65 - The Dwinnex
How did Adaptive Biotechnologies Corp (ADPT) fare last session? - US Post News
Adaptive Biotechnologies (ADPT) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
The Goldman Sachs Group Forecasts Strong Price Appreciation for Adaptive Biotechnologies (NASDAQ:ADPT) Stock - MarketBeat
The Goldman Sachs Group Increases Adaptive Biotechnologies (NASDAQ:ADPT) Price Target to $7.50 - Defense World
The 5.4% return this week takes Adaptive Biotechnologies' (NASDAQ:ADPT) shareholders one-year gains to 99% - Yahoo Finance
Why Adaptive Biotechnologies Corporation (ADPT) Is Skyrocketing Now - Insider Monkey
Why Is Andreas Halvorsen Bullish On Adaptive Biotechnologies Corporation (ADPT) Now? - Insider Monkey
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025 - Yahoo Finance
Adaptive Biotechnologies (NASDAQ:ADPT) Hits New 52-Week HighHere's What Happened - MarketBeat
Adaptive Biotechnologies stock hits 52-week high at $7.47 - Investing.com
Adaptive Biotechnologies (NASDAQ:ADPT) Shares Up 7.1%Still a Buy? - MarketBeat
Adaptive Biotechnologies Corp (NASDAQ: ADPT) Drops -1.59 Percent In Recent Trading, What Questions Do You Have? – Stocks Register - Stocks Register
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Sold by JPMorgan Chase & Co. - Defense World
Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Adaptive Biotechnologies (ADPT) Soars 18.0%: Is Further Upside Left in the Stock? - MSN
Adaptive Biotechnologies (NASDAQ:ADPT) Shares Up 17.6%Time to Buy? - MarketBeat
Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year - Benzinga
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Down 6.5%What's Next? - MarketBeat
Adaptive Biotechnologies and NeoGenomics partner to expand access to disease monitoring for blood cancer patients - Seeking Alpha
Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients - Yahoo Finance
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Acquired by Barclays PLC - MarketBeat
Cathie Wood's Ark Invest Trims Palantir Again As Peter Thiel Co-Founded Firm's Stock Tumbles Nearly 15% In 2025 - Benzinga India
Adaptive Biotechnologies: 1Q Earnings Snapshot -May 12, 2020 at 04:27 pm EDT - Marketscreener.com
Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics Which Laid Off Over A Quarter Of Its Workforce - Benzinga
Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025 - Yahoo Finance
Adaptive Biotechnologies (NASDAQ:ADPT) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Adaptive Biotechnologies stock hits 52-week high at $7.08 By Investing.com - Investing.com Australia
Adaptive Biotechnologies (NASDAQ:ADPT) Hits New 12-Month HighStill a Buy? - MarketBeat
Adaptive Biotechnologies stock hits 52-week high at $7.08 - Investing.com
Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Yahoo Finance
Adaptive Biotechnologies (NASDAQ:ADPT) Trading 7.3% HigherHere's Why - MarketBeat
Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Geode Capital Management LLC Sells 20,450 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Sees Significant Drop in Short Interest - Defense World
Seattle InnoAdaptive's royalty financing I Changes at Tanium - The Business Journals
Barclays PLC Has $1.18 Million Stake in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Stock Holdings Lifted by Barclays PLC - MarketBeat
Adaptive Biotechnologies Corporation Provides MRD Business Revenue Guidance for the Full Year 2024 - Marketscreener.com
State Street Corp Acquires 48,885 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Sold by Jane Street Group LLC - Defense World
Adaptive Biotechnologies (NASDAQ:ADPT) vs. Moderna (NASDAQ:MRNA) Financial Comparison - Defense World
BTIG Research Raises Adaptive Biotechnologies (NASDAQ:ADPT) Price Target to $9.00 - Defense World
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Down 6.6%What's Next? - MarketBeat
Are Medical Stocks Lagging BellRing Brands (BRBR) This Year? - Yahoo Finance
Charles Schwab Investment Management Inc. Purchases 10,262 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies Corp Stock (ADPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Adaptive Biotechnologies Corp Stock (ADPT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BOBULSKY SUSAN | Chief Commercial Officer, MRD |
Oct 08 '24 |
Option Exercise |
1.98 |
5,000 |
9,900 |
253,290 |
| Taylor Stacy L | SVP and General Counsel |
Aug 22 '24 |
Sale |
4.50 |
26,922 |
121,079 |
139,365 |
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):